Ocugen, Inc. (OCGN) shareholders
Close on Nov 16, 2026Market cap $262.13MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 26,952,492 | 8.00% | 13G (passive) | Jun 30, 2026 |
| State Street Corporation | 21,469,307 | 6.30% | 13G (passive) | Jun 30, 2026 |
| Janus Henderson Group PLC | 20,000,000 | 6.00% | 13G (passive) | Nov 28, 2025 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (5.20%), Israel A. Englander (5.20%) | 17,074,584 | 5.20% | 13G (passive) | Apr 9, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of OCGN | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 27,002,933 | 7.96% | $41.31M | +19,697,954 | 0.00% |
| State Street Corp | 21,469,307 | 6.33% | $32.85M | +11,799,116 | 0.00% |
| Vanguard Capital Management LLC | 14,372,598 | 4.24% | $21.99M | +568,487 | 0.00% |
| Millennium Management LLC | 13,943,252 | 4.11% | $21.33M | +216,060 | 0.01% |
| Geode Capital Management, LLC | 8,871,013 | 2.62% | $13.58M | +4,643,909 | 0.00% |
| Rtw Investments, LP | 6,666,666 | 1.97% | $10.20M | – | 0.09% |
| UBS Group AG | 5,177,508 | 1.53% | $7.92M | −2,102,812 | 0.00% |
| Ikarian Capital, LLC | 3,962,972 | 1.17% | $6.06M | – | 0.65% |
| Gmt Capital Corp | 3,505,398 | 1.03% | $5.36M | – | 0.28% |
| Marshall Wace, Llp | 3,410,257 | 1.01% | $5.22M | −4,642,093 | 0.00% |
| Vanguard Portfolio Management LLC | 3,329,446 | 0.98% | $5.09M | +2,393,647 | 0.00% |
| Hennion & Walsh Asset Management, Inc. | 2,830,397 | 0.83% | $4.33M | +1,553,672 | 0.12% |
| Northern Trust Corp | 2,747,562 | 0.81% | $4.20M | +2,033,826 | 0.00% |
| Vanguard Fiduciary Trust Co | 2,367,144 | 0.70% | $3.62M | +366,041 | 0.00% |
| Two Sigma Investments, LP | 2,230,179 | 0.66% | $3.41M | −21,103 | 0.00% |
| Qube Research & Technologies Ltd | 2,203,407 | 0.65% | $3.37M | −1,569,659 | 0.00% |
| Bank Of America Corp /De/ | 1,990,636 | 0.59% | $3.05M | +816,456 | 0.00% |
| Hrt Financial LP | 1,768,297 | 0.52% | $2.71M | +1,391,703 | 0.00% |
| Boothbay Fund Management, LLC | 1,097,742 | 0.32% | $1.68M | – | 0.02% |
| Charles Schwab Investment Management Inc | 1,042,537 | 0.31% | $1.60M | +830,443 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 147 | 145M | 42.8% | 43 / 46 | 27 / 31 | 54M | 20M |
| Q1 2026 | 137 | 111M | 32.7% | 47 / 43 | 21 / 16 | 73M | 7M |
| Q4 2025 | 109 | 62M | 18.2% | 30 / 33 | 19 / 14 | 23M | 7M |
| Q3 2025 | 97 | 46M | 13.5% | 18 / 21 | 35 / 24 | 4M | 11M |
| Q2 2025 | 104 | 52M | 15.4% | 33 / 28 | 25 / 39 | 14M | 39M |
| Q1 2025 | 110 | 77M | 22.6% | 18 / 38 | 29 / 21 | 10M | 5M |
| Q4 2024 | 114 | 72M | 21.1% | 26 / 31 | 29 / 25 | 8M | 16M |
| Q3 2024 | 115 | 80M | 23.5% | 32 / 34 | 22 / 17 | 32M | 2M |
| Q2 2024 | 101 | 67M | 19.9% | 44 / 24 | 12 / 23 | 42M | 9M |
| Q1 2024 | 81 | 35M | 10.2% | 27 / 24 | 7 / 14 | 11M | 3M |
| Q4 2023 | 68 | 27M | 7.9% | 11 / 16 | 19 / 21 | 1M | 8M |
| Q3 2023 | 78 | 33M | 9.7% | 5 / 20 | 22 / 23 | 1M | 17M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
73 funds held OCGN in Q2 2026, 87% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of OCGN | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 13,986,418 | 4.12% | $21.40M | 0.20% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 10,177,094 | 3.00% | $15.57M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 8,719,964 | 2.57% | $13.34M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 3,882,893 | 1.15% | $5.94M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 3,707,354 | 1.09% | $4.56M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 2,209,874 | 0.65% | $3.38M | 0.02% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P Kensho New Economies Composite ETF | 1,818,215 | 0.54% | $2.78M | 0.10% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,704,694 | 0.50% | $2.35M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 1,147,893 | 0.34% | $1.76M | 0.12% | Jun 30, 2026 |
| iShares Russell 2000 Value ETF | 996,712 | 0.29% | $1.52M | 0.01% | Jun 30, 2026 |
| Vanguard Health Care Index Fund | 931,671 | 0.27% | $1.29M | 0.01% | May 31, 2026 |
| Schwab Small-Cap Index Fund | 830,799 | 0.24% | $1.02M | 0.01% | Jul 31, 2026 |
| iShares Genomics Immunology and Healthcare ETF | 723,783 | 0.21% | $890.25K | 0.47% | Jul 31, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 661,597 | 0.20% | $1.01M | 0.00% | Jun 30, 2026 |
| Master Small Cap Index Series | 638,829 | 0.19% | $977.41K | 0.02% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Shankar Musunuri | Chief Executive Officer, Director | 5,049,241 | 1.49% | Oct 13, 2026 |
| Treerita Essalima Johnson-Greene | Chief Financial Officer | 521,350 | 0.15% | Jun 17, 2026 |
| Ramesh Ramachandran | Chief Accounting Officer | 209,100 | 0.06% | Jan 6, 2026 |
| Arun Upadhyay | See Remarks | 306,197 | 0.09% | Jan 6, 2025 |
| Huma Qamar | Chief Medical Officer | 1,643 | 0.00% | Jan 6, 2025 |
| Junge Zhang | Director | 2,369,569 | 0.70% | Jun 15, 2026 |
| Kirsten Castillo | Director | 75,000 | 0.02% | Jun 15, 2026 |
| Uday Kompella | Director | 705,090 | 0.21% | Jun 15, 2026 |
| Satishchandran Chandrasekhar | Director | – | – | Jun 15, 2026 |
| Blaise Coleman | Director | – | – | Jun 15, 2026 |
| Prabhavathi Fernandes | Director | 10,000 | 0.00% | Dec 2, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Shankar Musunuri Chief Executive Officer, Director | Oct 9, 2026 | Sale(10b5-1 plan) | −57,264 | $0.95 | $54.40K | 1,030,771 |
| Shankar Musunuri Chief Executive Officer, Director | Oct 9, 2026 | Sale(10b5-1 plan) | −468,727 | $0.95 | $445.29K | 4,018,470 |
| Shankar Musunuri Chief Executive Officer, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −57,264 | $1.12 | $64.14K | 1,088,035 |
| Shankar Musunuri Chief Executive Officer, Director | Sep 9, 2026 | Sale(10b5-1 plan) | −468,727 | $1.12 | $524.97K | 4,487,197 |
| Treerita Essalima Johnson-Greene Chief Financial Officer | Jun 15, 2026 | Buy | +21,000 | $1.23 | $25.83K | 521,000 |
| Junge Zhang Director | Apr 1, 2026 | Option exercise | +112,205 | $0.46 | $51.61K | 1,292,387 |
| Junge Zhang Director | Apr 1, 2026 | Option exercise | +15,000 | $0.51 | $7.65K | 1,180,182 |
| Junge Zhang Director | Apr 1, 2026 | Option exercise | +66,929 | $1.42 | $95.04K | 1,359,316 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 2, 2026 | Award | +3,123,201 | – | – | 4,955,924 |
| Ramesh Ramachandran Chief Accounting Officer | Jan 2, 2026 | Award | +207,300 | – | – | 209,100 |
| Arun Upadhyay See Remarks | Jan 3, 2025 | Tax withholding | −41,633 | $0.89 | $37.05K | 306,197 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 3, 2025 | Tax withholding | −177,146 | $0.89 | $157.66K | 1,832,723 |
| Prabhavathi Fernandes Director | Nov 26, 2024 | Buy | +10,000 | $0.91 | $9.10K | 10,000 |
| Kirsten Castillo Director | Nov 22, 2024 | Buy | +25,000 | $0.91 | $22.75K | 75,000 |
| Arun Upadhyay See Remarks | Sep 16, 2024 | Tax withholding | −842 | $1.17 | $985 | 347,830 |
| Arun Upadhyay See Remarks | Jun 17, 2024 | Tax withholding | −917 | $1.42 | $1.30K | 348,672 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 3, 2024 | Tax withholding | −180,204 | $0.65 | $117.13K | 2,009,869 |
| Arun Upadhyay See Remarks | Jan 3, 2024 | Tax withholding | −41,633 | $0.65 | $27.06K | 349,589 |
| Arun Upadhyay See Remarks | Sep 16, 2023 | Tax withholding | −842 | $0.41 | $345 | 391,222 |
| Arun Upadhyay Chief Scientific Officer | Jun 16, 2023 | Tax withholding | −917 | $0.51 | $468 | 392,064 |
| Junge Zhang Director | Jun 14, 2023 | Buy | +200,278 | $0.50 | $100.14K | 1,077,182 |
| Shankar Musunuri Chief Executive Officer, Director | Feb 16, 2023 | Sale(10b5-1 plan) | −100,000 | $1.08 | $108.00K | 2,190,073 |
| Shankar Musunuri Chief Executive Officer, Director | Feb 16, 2023 | Option exercise | +100,000 | $0.33 | $33.00K | 2,290,073 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 17, 2023 | Option exercise | +100,000 | $0.51 | $51.00K | 2,327,950 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 17, 2023 | Sale(10b5-1 plan) | −100,000 | $1.28 | $128.00K | 2,227,950 |
| Jessica Crespo CAO/SVP, Finance | Jan 3, 2023 | Tax withholding | −1,913 | $1.25 | $2.39K | 161,478 |
| Arun Upadhyay Chief Scientific Officer | Jan 3, 2023 | Tax withholding | −7,102 | $1.25 | $8.88K | 392,981 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 3, 2023 | Tax withholding | −37,877 | $1.25 | $47.35K | 2,190,073 |
| Jessica Crespo CAO/SVP, Finance | Jan 3, 2023 | Award | +122,951 | – | – | 163,391 |
| Arun Upadhyay Chief Scientific Officer | Jan 3, 2023 | Award | +315,924 | – | – | 400,083 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 3, 2023 | Award | +1,475,410 | – | – | 2,227,950 |
| Shankar Musunuri Chief Executive Officer, Director | Dec 16, 2022 | Option exercise | +95,809 | $0.51 | $48.86K | 848,349 |
| Shankar Musunuri Chief Executive Officer, Director | Dec 16, 2022 | Sale(10b5-1 plan) | −95,809 | $1.43 | $137.01K | 752,540 |
| Shankar Musunuri Chief Executive Officer, Director | Oct 14, 2022 | Sale(10b5-1 plan) | −100,000 | $1.66 | $166.00K | 752,540 |
| Shankar Musunuri Chief Executive Officer, Director | Oct 14, 2022 | Option exercise | +100,000 | $0.51 | $51.00K | 852,540 |
| Ramesh Kumar Director | Oct 6, 2022 | Sale(10b5-1 plan) | −4,500 | $1.83 | $8.24K | 0 |
| Ramesh Kumar Director | Oct 6, 2022 | Option exercise | +4,500 | $0.51 | $2.30K | 4,500 |
| Kirsten Castillo Director | Aug 11, 2022 | Option exercise | +42,000 | $0.28 | $11.76K | 92,000 |
| Kirsten Castillo Director | Aug 11, 2022 | Sale | −42,000 | $2.91 | $122.22K | 50,000 |
| Ramesh Kumar Director | Jul 18, 2022 | Option exercise | +7,500 | $0.51 | $3.83K | 7,500 |
| Ramesh Kumar Director | Jul 18, 2022 | Sale(10b5-1 plan) | −7,500 | $2.57 | $19.28K | 0 |
| Shankar Musunuri Chief Executive Officer, Director | Jul 14, 2022 | Sale(10b5-1 plan) | −150,000 | $2.72 | $408.00K | 752,540 |
| Shankar Musunuri Chief Executive Officer, Director | Jul 14, 2022 | Option exercise | +150,000 | $0.33 | $49.50K | 902,540 |
| Shankar Musunuri Chief Executive Officer, Director | May 13, 2022 | Sale(10b5-1 plan) | −125,000 | $1.92 | $240.00K | 752,540 |
| Shankar Musunuri Chief Executive Officer, Director | May 13, 2022 | Option exercise | +125,000 | $0.33 | $41.25K | 877,540 |
| Ramesh Kumar Director | Apr 18, 2022 | Sale(10b5-1 plan) | −7,500 | $2.83 | $21.23K | 0 |
| Ramesh Kumar Director | Apr 18, 2022 | Option exercise | +7,500 | $0.51 | $3.83K | 7,500 |
| Jessica Crespo CAO/SVP, Finance | Mar 18, 2022 | Award | +22,940 | – | – | 40,440 |
| Shankar Musunuri Chief Executive Officer, Director | Mar 16, 2022 | Option exercise | +81,823 | $0.33 | $27.00K | 834,363 |
| Shankar Musunuri Chief Executive Officer, Director | Mar 16, 2022 | Sale(10b5-1 plan) | −81,823 | $2.65 | $216.83K | 752,540 |
| Junge Zhang Director | Mar 3, 2022 | Option exercise | +39,000 | $0.51 | $19.89K | 39,000 |
| Junge Zhang Director | Mar 3, 2022 | Option exercise | +49,000 | $1.83 | $89.67K | 88,000 |
| Shankar Musunuri Chief Executive Officer, Director | Feb 14, 2022 | Sale(10b5-1 plan) | −90,000 | $3.74 | $336.60K | 752,540 |
| Shankar Musunuri Chief Executive Officer, Director | Feb 14, 2022 | Option exercise | +90,000 | $0.33 | $29.70K | 842,540 |
| Ramesh Kumar Director | Jan 18, 2022 | Option exercise | +7,500 | $0.51 | $3.83K | 7,500 |
| Ramesh Kumar Director | Jan 18, 2022 | Sale(10b5-1 plan) | −7,500 | $4.07 | $30.53K | 0 |
| Sanjay Subramanian Chief Financial Officer | Jan 3, 2022 | Award | +125,534 | – | – | 161,125 |
| Shankar Musunuri Chief Executive Officer, Director | Jan 3, 2022 | Award | +346,540 | – | – | 752,540 |
| Manish Potti Director | Dec 16, 2021 | Option exercise | +31,500 | $1.83 | $57.65K | 45,000 |
| Manish Potti Director | Dec 16, 2021 | Option exercise | +13,500 | $0.51 | $6.89K | 13,500 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ocugen's stock actually held short. Settlement fails (shares not delivered on time) peaked at 603,805 shares on Oct 13, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Shankar Musunuri Officer | Oct 9, 2026 | 525,991 | $497.96K | Oct 9, 2026 | Equity Compensation |
| Shankar Musunuri Officer | Sep 9, 2026 | 525,991 | $589.74K | Sep 9, 2026 | Equity Compensation |
| Marna C. Whittington Director | Jul 9, 2025 | 112,205 | $122.89K | Jul 9, 2025 | Stock Option Exercise |
| Prabhavathi Fernandes Director | Jun 11, 2025 | 146,705 | $171.03K | Jun 11, 2025 | Stock Option Exercise |
| Ramesh Kumar Director | Aug 16, 2024 | 116,705 | $145.90K | Aug 16, 2024 | Stock Option Exercise |
Congress trades
2 trades in Ocugen reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Sold | Nov 8, 2022 | $1K–15K | Dec 12, 2022 |
| Christopher L. Jacobs NY27 | Bought | Jun 16, 2022 | $15K–50K | Jul 28, 2022 |
See a number that looks wrong?